| HOME >> BIOLOGY >> TECHNOLOGY |
Location: S Hall A1
Poster Number: 42H Abstract Number: 8053
Presenter: Naiyer A Rizvi, MD
Monday, June 2
-- XL647 (EGFR, HER2, VEGFR2) - Poster & Discussion
"Activity and tolerance of XL647 in NSCLC patients with acquired
resistance to EGFR-TKIs: Preliminary results of a phase 2 trial"
Day: Monday, June 2
Session: Lung Cancer -- Metastatic
Time (Poster): 8 a.m.-noon Location: W375e Lobby
Time (Discussion): Noon-12:15 p.m. Location: W375d
Poster Number: 9 Abstract Number: 8028
Presenter: Vincent A. Miller, MD
-- XL880* (MET, VEGFR2) -- Poster
"Preliminary activity of GSK1363089 (XL880), a dual MET/VEGFR2
inhibitor, in MET amplified poorly differentiated gastric cancer
(PDGC): Interim results of a multicenter phase 2 study"
Day: Monday, June 2
Session: Gastrointestinal (Noncolorectal) Cancer
Time: 8 a.m.-noon
Location: S Hall A1
Poster Number: 33D Abstract Number: 4572
Presenter: Minaxi P. Jhawer, MD
* XL880 was selected by GlaxoSmithKline in December 2007 for further
development and commercialization.
About Exelixis
Exelixis, Inc. is a development-stage biotechnology company dedicated
to the discovery and development of novel small molecule therapeutics for
the treatment of cancer and other serious diseases. The company is
leveraging its fully integrated drug discovery platform to fuel the growth
of its development pipeline, which is primarily focused on cancer.
Currently, Exelixis' broad product pipeline includes investigational
compounds in phase 2 and phase 1 clinical development. Exelixis has
established strategic corporate alliances with major pharmaceutical and
biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb,
Genentech, Wyeth Pharmaceuticals, and Daiichi-Sankyo. For more information,
p
'/>"/>
| SOURCE Exelixis, Inc. Copyright©2008 PR Newswire. All rights reserved |